Articles Found

Page: 1 2 3 4 5 6 7 8 9 10 ... Next »

Recent Articles   Industry   Published  Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma Pharma / BioTech / Nutrition 2026/01/21 More New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS Pharma / BioTech / Nutrition 2026/01/15 More Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients Pharma / BioTech / Nutrition 2026/01/14 More U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia Pharma / BioTech / Nutrition 2026/01/13 More Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea Pharma / BioTech / Nutrition 2026/01/13 More BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions Pharma / BioTech / Nutrition 2026/01/12 More Ipsen Expands Early Development Pipeline with Simcere Zaiming’s Innovative Antibody Drug Conjugate Pharma / BioTech / Nutrition 2025/12/22 More Ipsen Update on Phase II FALKON Trial in Patients with Ultra-rare Bone Disease, Fibrodysplasia Ossificans Progressiva (FOP) Pharma / BioTech / Nutrition 2025/12/19 More Ipsen Completes Acquisition of ImCheck Therapeutics, Expanding Oncology Pipeline Pharma / BioTech / Nutrition 2025/12/15 More NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025 Pharma / BioTech / Nutrition 2025/12/10 More Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera Pharma / BioTech / Nutrition 2025/12/08 More JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information Pharma / BioTech / Nutrition 2025/11/28 More Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer Pharma / BioTech / Nutrition 2025/11/20 More WuXi AppTec Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition in the CRDMO Industry Pharma / BioTech / Nutrition 2025/11/19 More Frost Radar™ Identifies Top Growth and Innovation Leaders in Pharmaceutical and Biotech Laboratory Information Management Systems Pharma / BioTech / Nutrition 2025/10/17 More

---

Page: 1 2 3 4 5 6 7 8 9 10 ... Next »